111, Inc. reports on a China-based, tech-enabled healthcare platform that connects consumers, pharmacies and healthcare partners through online and offline channels. The company’s recurring updates cover its B2B pharmaceutical sourcing platform, B2C online retail pharmacy activity, internet hospital services through 1 Clinic, and cloud-based services for offline pharmacies.
Company news also focuses on unaudited financial results, gross segment profit, operating expenses, cash flow, B2B gross margin trends and the transition toward an asset-light fulfillment partnership model. Other recurring topics include digital tools, supply-chain efficiency, drug commercialization services and Nasdaq ADR listing compliance matters.
On May 4, 2022, 111 Inc. (NASDAQ: YI) was provisionally listed as a "Commission-Identified Issuer" by the SEC under the Holding Foreign Companies Accountable Act. This follows the filing of its annual report on Form 20-F for the year ended December 31, 2021. The SEC's identification indicates that the Company used an auditor whose working papers are not fully inspectable by the PCAOB. If this is not addressed, trading of its securities may be prohibited on U.S. exchanges after three years. 111 Inc. is committed to maintaining compliance and protecting shareholder interests.
On April 13, 2022, 111, Inc. (NASDAQ: YI) announced its establishment of an 'Anti-Epidemic Command' to aid in Shanghai's COVID-19 response. The company has implemented various services including antigen test supplies, chronic disease medication registration, and online consultations. Following an initial shipment of essential items on April 7, 111 has enhanced its logistics for fast delivery. The online platform, 1 Pharmacy, offers over 100,000 drugs, while 1 Clinic provides virtual consultations. Dr. Yu Gang emphasized the company's commitment to support Shanghai's healthcare needs during the pandemic.
111, Inc. (YI) reported its Q4 and full-year 2021 financial results, highlighting a 30.9% YoY increase in net revenues to RMB 3.46 billion (US$ 543.1 million) for Q4, and a 51.5% YoY increase to RMB 12.4 billion (US$ 1.95 billion) for the fiscal year. Gross segment profit surged 98% YoY in Q4, with a 70% increase annually. Notably, the company expanded its partnerships to 515 pharmaceutical companies. Despite a non-GAAP loss from operations of RMB 76.9 million (US$ 12.1 million), the loss margin improved significantly from 4.2% to 2.2% YoY.
On March 14, 2022, 111, Inc. (NASDAQ: YI) entered a strategic partnership with Shenzhen BGI Co., Ltd. to distribute SARS-CoV-2 Virus Antigen Detection Kits through its online pharmacy, 1 Pharmacy. This collaboration will make 1 Pharmacy the first online platform in China to offer these kits, starting pre-sales this week. This initiative aims to enhance epidemic prevention efforts across China by providing better access to testing resources directly to consumers via a digital platform.
On February 23, 2022, 111, Inc. (NASDAQ: YI) signed a strategic cooperation agreement with Xi'an Beilin Pharmaceutical Co., Ltd. This collaboration aims to enhance digital marketing and expand market access for Chinese patent medicines. Both companies will leverage their strengths to integrate resources, focusing on big data application and brand building. The partnership is expected to create new growth opportunities and improve accessibility for high-quality healthcare products in China.
111, Inc. (NASDAQ: YI) announced it will report its fourth quarter and fiscal year 2021 unaudited financial results on March 17, 2022, before the U.S. market opens. A conference call will follow at 7:30 AM ET on the same day. Participants must register in advance to receive dial-in information. 111, Inc. is a leading tech-enabled healthcare platform in China, providing access to pharmaceutical products and online healthcare services through its platforms including 1 Pharmacy and 1 Clinic.
111, Inc. (NASDAQ: YI) reported its Q3 2021 results, achieving net revenues of RMB3.35 billion (US$519.3 million), a 41.6% increase year-over-year. Service revenue surged 106%, with B2B services growing 336%. Gross profit rose 85% to a gross margin of 5.0%, driven by a 145% increase in B2B gross profit. Despite significant growth, the company faced a net loss of RMB165.8 million (US$25.7 million), up from RMB111.2 million last year. Looking ahead, Q4 revenues are expected to grow 30% to 40% year-over-year, projected to reach RMB3.44 billion to RMB3.70 billion.
Summary not available.
111, Inc. (NASDAQ: YI) will release its unaudited financial results for Q3 2021 on November 19, 2021, before U.S. market open. A conference call is scheduled at 7:30 AM ET on the same day, with registration required for participation. 111, Inc. operates a tech-enabled healthcare platform in China, connecting patients with medicines and healthcare services. The company runs an online retail pharmacy and an internet hospital, among other services, enhancing access to healthcare for consumers.
111, Inc. (NASDAQ: YI) has announced a strategic partnership with Chugai Pharma China to advance healthcare in China through innovative digital solutions. This collaboration aims to establish a 'SMART Healthcare City' concept, enhancing the treatment accessibility for chronic diseases. As the first e-commerce company to form such a partnership with Chugai, 111 will leverage its technological strengths to improve healthcare delivery. Both companies intend to align with China's 'Healthy China 2030' initiative, which targets comprehensive chronic disease management for better patient outcomes.